Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 1391-1399, April 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, J. M.
Right arrow Articles by Wouters, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, J. M.
Right arrow Articles by Wouters, B. G.
[Cancer Research 59, 1391-1399, April 1, 1999]
© 1999 American Association for Cancer Research

Review

Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents1

J. Martin Brown2 and Bradly G. Wouters

Cancer Biology Research Laboratory, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305

A widely held tenet of present day oncology is that tumor cells treated with anticancer agents die from apoptosis, and that cells resistant to apoptosis are resistant to cancer treatment. We suggest, in this review, that this tenet may need to be reexamined for human tumors of nonhematological origin, for two principal reasons: (a) cell killing has often been assessed in short term assays that are more influenced by the rate, than the overall level, of cell killing. This has tended to underestimate cell killing for cells not susceptible to apoptosis or having mutant p53; and (b) conclusions from experiments with normal cells transformed with dominant oncogenes have often been extrapolated to tumor cells. This does not take into account the fact that tumor cells have invariably undergone selection to an apoptotically resistant phenotype. In this review, we examine the impact of these two factors with particular emphasis on the influence of mutations in p53 on the sensitivity of tumor cells to DNA-damaging agents. We find that because wild-type p53 predisposes cells to a more rapid rate of cell death after DNA damage, particularly with normal or minimally transformed cells, that short-term assays have led to the conclusion that mutations in p53 confer resistance to genotoxic agents. On the other hand, if clonogenic survival is used to assess killing in cells derived from actual solid human tumors, then apoptosis and the genes controlling it, such as p53 and bcl-2, appear to play little or no role in the sensitivity of these cells to killing by anticancer drugs and radiation.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. Toulany, R. Kehlbach, U. Florczak, A. Sak, S. Wang, J. Chen, M. Lobrich, and H. P. Rodemann
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
Mol. Cancer Ther., July 1, 2008; 7(7): 1772 - 1781.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. S. Huang, S. Duan, E. O. Kistner, W. K. Bleibel, S. M. Delaney, D. L. Fackenthal, S. Das, and M. E. Dolan
Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity
Cancer Res., May 1, 2008; 68(9): 3161 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Apel, I. Herr, H. Schwarz, H. P. Rodemann, and A. Mayer
Blocked Autophagy Sensitizes Resistant Carcinoma Cells to Radiation Therapy
Cancer Res., March 1, 2008; 68(5): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
S. Bhana and D. R. Lloyd
The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts
Mutagenesis, January 1, 2008; 23(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M.-S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, A. Sakurada, M. Whitehead, C.-Q. Zhu, R. Livingston, D. H. Johnson, et al.
Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5240 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Meslin, J. Thiery, C. Richon, A. Jalil, and S. Chouaib
Granzyme B-induced Cell Death Involves Induction of p53 Tumor Suppressor Gene and Its Activation in Tumor Target Cells
J. Biol. Chem., November 9, 2007; 282(45): 32991 - 32999.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Garner, F. Martinon, J. Tschopp, P. Beard, and K. Raj
Cells with Defective p53-p21-pRb Pathway Are Susceptible to Apoptosis Induced by p84N5 via Caspase-6
Cancer Res., August 15, 2007; 67(16): 7631 - 7637.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Marusyk, L. J. Wheeler, C. K. Mathews, and J. DeGregori
p53 Mediates Senescence-Like Arrest Induced by Chronic Replicational Stress
Mol. Cell. Biol., August 1, 2007; 27(15): 5336 - 5351.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. L. Nguyen, R. M. Kraft, and J. A. Blaho
Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis
J. Gen. Virol., July 1, 2007; 88(7): 1866 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A Di Leo, M Tanner, C Desmedt, M Paesmans, F Cardoso, V Durbecq, S Chan, T Perren, M Aapro, C Sotiriou, et al.
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial
Ann. Onc., June 1, 2007; 18(6): 997 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Q. Cheng, X. Luo, B. Zhang, X. Jiang, B. Yi, and M. Wu
Distal Bile Duct Carcinoma: Prognostic Factors After Curative Surgery. A Series of 112 Cases
Ann. Surg. Oncol., March 1, 2007; 14(3): 1212 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. A. Levesque and A. Eastman
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Carcinogenesis, January 1, 2007; 28(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Fischer, E. M. Mihelc, K. E. Pollok, and M. L. Smith
Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair
Mol. Cancer Ther., January 1, 2007; 6(1): 355 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cao, T. Subhawong, J. M. Albert, K. W. Kim, L. Geng, K. R. Sekhar, Y. J. Gi, and B. Lu
Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells.
Cancer Res., October 15, 2006; 66(20): 10040 - 10047.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. Menendez, A. Inga, and M. A. Resnick
The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes.
Mol. Cell. Biol., March 1, 2006; 26(6): 2297 - 2308.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Shibata, K. Iio, Y. Kawai, N. Shibata, M. Kawaguchi, S. Toi, M. Kobayashi, M. Kobayashi, K. Yamamoto, and K. Uchida
Identification of a Lipid Peroxidation Product as a Potential Trigger of the p53 Pathway
J. Biol. Chem., January 13, 2006; 281(2): 1196 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Lee, C. B. Fuhrman, V. Planelles, M. R. Peltier, D. K. Gaffney, A. P. Soisson, M. K. Dodson, H. D. Tolley, C. L. Green, and K. A. Zempolich
Phosphatidylinositol 3-Kinase Inhibition by LY294002 Radiosensitizes Human Cervical Cancer Cell Lines
Clin. Cancer Res., January 1, 2006; 12(1): 250 - 256.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. C. Kaul, S. Aida, T. Yaguchi, K. Kaur, and R. Wadhwa
Activation of Wild Type p53 Function by Its Mortalin-binding, Cytoplasmically Localizing Carboxyl Terminus Peptides
J. Biol. Chem., November 25, 2005; 280(47): 39373 - 39379.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. N. Putral, M. J. Bywater, W. Gu, N. A. Saunders, B. G. Gabrielli, G. R. Leggatt, and N. A. J. McMillan
RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplatin
Mol. Pharmacol., November 1, 2005; 68(5): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Morse, H. Gray, C. M. Payne, and R. J. Gillies
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1495 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. F. Aguero, M. M. Facchinetti, Z. Sheleg, and A. M. Senderowicz
Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1
Cancer Res., April 15, 2005; 65(8): 3364 - 3373.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
J. M. Brown
Drug Resistance: The Role of Genes Involved in Apoptosis
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 119 - 122.
[Full Text] [PDF]

Home page
 aacrmtgHome page
M. Brown
How much is apoptosis involved in the response of solid tumors to therapy?
AACR Meeting Abstracts, April 1, 2005; 2005(1): 1469 - 1470.
[Abstract]

Home page
 CarcinogenesisHome page
R. Gerl and D. L. Vaux
Apoptosis in the development and treatment of cancer
Carcinogenesis, February 1, 2005; 26(2): 263 - 270.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Thiery, S. Abouzahr, G. Dorothee, A. Jalil, C. Richon, I. Vergnon, F. Mami-Chouaib, and S. Chouaib
p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways
J. Immunol., January 15, 2005; 174(2): 871 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Zhuo, N. Zheng, C. A. Felix, and I. A. Blair
KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM
Drug Metab. Dispos., September 1, 2004; 32(9): 993 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. B. Werner, S. W. G. Tait, E. de Vries, E. Eldering, and J. Borst
Requirement for Aspartate-cleaved Bid in Apoptosis Signaling by DNA-damaging Anti-cancer Regimens
J. Biol. Chem., July 2, 2004; 279(27): 28771 - 28780.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Egle, A. W. Harris, P. Bouillet, and S. Cory
Bim is a suppressor of Myc-induced mouse B cell leukemia
PNAS, April 20, 2004; 101(16): 6164 - 6169.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Schneider-Stock, C. Mawrin, C. Motsch, C. Boltze, B. Peters, R. Hartig, P. Buhtz, A. Giers, A. Rohrbeck, B. Freigang, et al.
Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer
Am. J. Pathol., April 1, 2004; 164(4): 1233 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Kramer, H. Erdal, H. J. M. M. Mertens, M. Nap, J. Mauermann, G. Steiner, M. Marberger, K. Biven, M. C. Shoshan, and S. Linder
Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18
Cancer Res., March 1, 2004; 64(5): 1751 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zheng, P. M. Chou, B. L. Mirkin, and A. Rebbaa
Senescence-initiated Reversal of Drug Resistance: Specific Role of Cathepsin L
Cancer Res., March 1, 2004; 64(5): 1773 - 1780.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Starenki, H. Namba, V. Saenko, A. Ohtsuru, and S. Yamashita
Inhibition of Nuclear Factor-{kappa}B Cascade Potentiates the Effect of a Combination Treatment of Anaplastic Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 410 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Vekris, D. Meynard, M.-C. Haaz, M. Bayssas, J. Bonnet, and J. Robert
Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of in Silico Research
Cancer Res., January 1, 2004; 64(1): 356 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. Marabese, F. Vikhanskaya, C. Rainelli, T. Sakai, and M. Broggini
DNA damage induces transcriptional activation of p73 by removing C-EBP{alpha} repression on E2F1
Nucleic Acids Res., November 15, 2003; 31(22): 6624 - 6632.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Sheard, S. Uldrijan, and B. Vojtesek
Role of p53 in Regulating Constitutive and X-Radiation-Inducible CD95 Expression and Function in Carcinoma Cells
Cancer Res., November 1, 2003; 63(21): 7176 - 7184.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Chen, K. S. Koeneman, and D. R. Corey
Consequences of Telomerase Inhibition and Combination Treatments for the Proliferation of Cancer Cells
Cancer Res., September 15, 2003; 63(18): 5917 - 5925.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
K. Tsuruya, M. Tokumoto, T. Ninomiya, M. Hirakawa, K. Masutani, M. Taniguchi, K. Fukuda, H. Kanai, H. Hirakata, and M. Iida
Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways
Am J Physiol Renal Physiol, August 1, 2003; 285(2): F208 - F218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Ott, H. Vogelsang, J. Mueller, K. Becker, M. Muller, U. Fink, J. R. Siewert, H. Hofler, and G. Keller
Chromosomal Instability Rather Than p53 Mutation Is Associated with Response to Neoadjuvant Cisplatin-based Chemotherapy in Gastric Carcinoma
Clin. Cancer Res., June 1, 2003; 9(6): 2307 - 2315.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
O. S. Frankfurt and A. Krishan
Microplate Screening for Apoptosis with Antibody to Single-Stranded DNA Distinguishes Anticancer Drugs from Toxic Chemicals
J Biomol Screen, April 1, 2003; 8(2): 185 - 190.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
A. Ito, Y.-i. Koma, K. Watabe, T. Nagano, Y. Endo, H. Nojima, and Y. Kitamura
A Truncated Isoform of the Protein Phosphatase 2A B56{gamma} Regulatory Subunit May Promote Genetic Instability and Cause Tumor Progression
Am. J. Pathol., January 1, 2003; 162(1): 81 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Koivusalo, E. Krausz, P. Ruotsalainen, H. Helenius, and S. Hietanen
Chemoradiation of Cervical Cancer Cells: Targeting Human Papillomavirus E6 and p53 Leads to Either Augmented or Attenuated Apoptosis Depending on the Platinum Carrier Ligand
Cancer Res., December 15, 2002; 62(24): 7364 - 7371.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. R. Seo, M. R. Kelley, and M. L. Smith
From the Cover: Selenomethionine regulation of p53 by a ref1-dependent redox mechanism
PNAS, October 29, 2002; 99(22): 14548 - 14553.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Bronder and R. G. Moran
Antifolates Targeting Purine Synthesis Allow Entry of Tumor Cells into S Phase Regardless of p53 Function
Cancer Res., September 15, 2002; 62(18): 5236 - 5241.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al.
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
Ann. Onc., July 1, 2002; 13(7): 1108 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Kitagawa, S. Yamaguchi, M. Hasegawa, K. Tanaka, T. Sado, K. Hirokawa, and S. Aizawa
Friend Leukemia Virus Infection Enhances DNA Damage-Induced Apoptosis of Hematopoietic Cells, Causing Lethal Anemia in C3H Hosts
J. Virol., June 27, 2002; 76(15): 7790 - 7798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Kondo, T. Shibata, T. Kumagai, T. Osawa, N. Shibata, M. Kobayashi, S. Sasaki, M. Iwata, N. Noguchi, and K. Uchida
15-Deoxy-Delta 12,14-prostaglandin J2: The endogenous electrophile that induces neuronal apoptosis
PNAS, May 28, 2002; 99(11): 7367 - 7372.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Han, W. Wei, S. Dunaway, J. W. Darnowski, P. Calabresi, J. Sedivy, E. A. Hendrickson, K. V. Balan, P. Pantazis, and J. H. Wyche
Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin
J. Biol. Chem., May 3, 2002; 277(19): 17154 - 17160.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Bravard, A. Ageron-Blanc, S. Alvarez, P. Drane, Y. le Rhun, F. Paris, C. Luccioni, and E. May
Correlation between antioxidant status, tumorigenicity and radiosensitivity in sister rat cell lines
Carcinogenesis, May 1, 2002; 23(5): 705 - 711.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P.-F. Cartron, L. Oliver, S. Martin, C. Moreau, M.-T. LeCabellec, P. Jezequel, K. Meflah, and F. M. Vallette
The expression of a new variant of the pro-apoptotic molecule Bax, Bax{psi}, is correlated with an increased survival of glioblastoma multiforme patients
Hum. Mol. Genet., March 1, 2002; 11(6): 675 - 687.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
M. L. Smith and Y. R. Seo
p53 regulation of DNA excision repair pathways
Mutagenesis, March 1, 2002; 17(2): 149 - 156.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. F. Pollack, S. D. Finkelstein, J. Woods, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. M. Boyett, J. L. Finlay, R. Sposto, et al.
Expression of p53 and Prognosis in Children with Malignant Gliomas
N. Engl. J. Med., February 7, 2002; 346(6): 420 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Chen, B. Shen, L. Xia, A. Khaletzkiy, D. Chu, J. Y. C. Wong, and J.-J. Li
Activation of Nuclear Factor {kappa}B in Radioresistance of TP53-inactive Human Keratinocytes
Cancer Res., February 1, 2002; 62(4): 1213 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Plath, M. Peters, K. Detjen, M. Welzel, Z. von Marschall, C. Radke, B. Wiedenmann, and S. Rosewicz
Overexpression of pRB in Human Pancreatic Carcinoma Cells: Function in Chemotherapy-Induced Apoptosis
J Natl Cancer Inst, January 16, 2002; 94(2): 129 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Green, W. E. Antholine, S. J. Wong, D. R. Richardson, and C. R. Chitambar
Inhibition of Malignant Cell Growth by 311, a Novel Iron Chelator of the Pyridoxal Isonicotinoyl Hydrazone Class: Effect on the R2 subunit of Ribonucleotide Reductase
Clin. Cancer Res., November 1, 2001; 7(11): 3574 - 3579.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Laurent and J.-P. Jaffrezou
Signaling pathways activated by daunorubicin
Blood, August 15, 2001; 98(4): 913 - 924.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fan, M. E. Goodwin, M. J. Birrer, and T. C. Chambers
The c-Jun NH2-terminal Protein Kinase/AP-1 Pathway Is Required for Efficient Apoptosis Induced by Vinblastine
Cancer Res., June 1, 2001; 61(11): 4450 - 4458.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Spring, S. Cross, C. Li, D. Watters, L. Ben-Senior, P. Waring, F. Ahangari, S.-l. Lu, P. Chen, I. Misko, et al.
Atm Knock-in Mice Harboring an In-frame Deletion Corresponding to the Human ATM 7636del9 Common Mutation Exhibit a Variant Phenotype
Cancer Res., June 1, 2001; 61(11): 4561 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Xu, C. L. Nutt, M. C. Zlatescu, M. Keeney, I. Chin-Yee, and J. G. Cairncross
Inactivation of p53 Sensitizes U87MG Glioma Cells to 1,3-bis(2-Chloroethyl)-1-nitrosourea
Cancer Res., May 1, 2001; 61(10): 4155 - 4159.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.